

## **R E M A R K S**

For the purpose of expediting prosecution, the subject matter of Claims 3 and 11 has been incorporated into Claim 1 without prejudice to the applicant's rights to seek protection for the subject matter of Claim 1 in a continuation application. The applicant does not agree that the specification lacks an enabling disclosure for a broad range of acetylcholineesterase inhibitors or that one skilled in the art can select such a compound based on the criteria given in the application. Nor does the applicant agree that patentability has not been shown for treatment of conditions benefitting from stimulation of the hypothalamic-pituitary-gonadal axis generally with acetylcholinesterase inhibitors rather than just treatment of failure of ovulation. The additional language added to Claim 1 beyond that coming from Claims 3 and 11 finds support at page 8, five lines from the bottom of the page.


The claims having been limited to the compounds specified in prior Claim 11, which has now been canceled, the rejection under 35 USC 112 is now moot.

Having regard to the 35 USC 103 rejection, the revised claims address the issues set out on page 13 of the final rejection and are believed therefore to place the application in order for allowance. The applicant does, however, wish to re-emphasize the point made in response to the previous action namely that one cannot take a report that, in rabbits, there is a post-coital increase of acetyl choline and acetylcholinesterase in blood as a teaching to use acetylcholinesterase inhibitors to induce ovulation in humans suffering from a failure to ovulate. While Saito states that "augmented cholinergic processes apparently stimulate the release of egg from the follicle", this is in the context of rabbits. Rabbits, but not humans, are reflex ovulators. Ovulation in rabbits follows coitus. This is not the case in humans where ovulation normally occurs as part of the menstrual cycle. This is a fundamental difference. One skilled in the art

would not be motivated to take Saito's observations as the basis for a treatment of humans.

In view of the foregoing, it is submitted that this application is now in order for allowance and an early action to this end is respectfully solicited.

Respectfully submitted,



JOHN RICHARDS  
LADAS & PARRY  
26 WEST 61<sup>ST</sup> STREET  
NEW YORK, NEW YORK 10023  
REG. 31053  
TEL. (212) 708-1915